HOME >> MEDICINE >> NEWS
Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, December 13 -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that the US Food & Drug Administration (FDA) has approved EQUETRO(TM) (extended-release carbamazepine capsules), previously known as SPD417, for the treatment of patients with Bipolar Disorder, ten months after submission.

Bipolar Disorder is one of the six leading mental disorders worldwide, according to the World Health Organization.[i] Each year, it is estimated that more than 2 million American adults[ii], [iii], about 1 percent of the population age 18 and older,[iv] are afflicted with Bipolar Disorder, also known as manic depression. Of the 750,000 currently diagnosed, about 650,000 are treated. The bipolar market in the United States is currently valued at about US$1.9bn and is expected to grow to $2.4bn by 2007(++).

Bipolar Disorder is characterized by episodes of mania and depression, with periods of normal mood in between. The disorder can have devastating effects on an individual's life, although proper diagnosis and earlier treatment can usually alter the course of the illness.

EQUETRO significantly reduces the manic symptoms in Bipolar patients. Additionally, in clinical trials, patients treated with the product demonstrated no clinically significant weight gain or increase in blood glucose levels, thereby creating an effective tolerability profile(+). The unique three-bead extended release delivery system of Equetro provides for convenient administration as well. Available in 100, 200 and 300mg dosage strengths, it is the only carbamazepine formulation proven effective for patients with Bipolar Disorder.

EQUETRO has a formulation patent that runs until 2011 and will have three years market exclusivity under the US Hatch-Waxman Act. It will be available for prescribing in the US in the first quarter of 2005.

Matthew Emmens, Chief Executive of Shire commented: "Bi
'"/>

Contact: Matthew Cabrey, Shire Pharmaceuticals plc
484-595-8248
Porter Novelli
13-Dec-2004


Page: 1 2

Related medicine news :

1. Shire receives approvable letter for adult ADDERALL XR(R) from FDA
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... ... featured in Biocompare’s latest content hub— Future Lab: COVID-19 R&D . , ... advancements, trends, news, and products within specific scientific niches. Since their launch four ...
(Date:7/2/2020)... ... 02, 2020 , ... Columbia Southern University (CSU), a leading ... to Eric Simmons of Temecula, California. , CSU’s occupational safety and health ... master’s degree in occupational safety and health from the university, is the corporate ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera Bioscience ... psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm ... novel formulations, and as distinguished researchers within the cannabis industry. They are joined ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... PathAI, a ... the results of an exploratory analysis of digital scoring of PD-L1 expression to assess ... a poster #2017 at the 2020 American Association for Cancer Research (AACR) Annual Meeting. ...
(Date:6/28/2020)... ... June 28, 2020 , ... ... the world, dedicates World Allergy Week, from June 28 to July 4, 2020, ... SARS CoV-2. , COVID-19, short for “coronavirus disease 2019”, is a disease spreading ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... Nonprofit Team PHenomenal Hope (Team PH) will announce ... its first ever virtual research town hall on Saturday, July 11 at noon EST. ... latest research in the area of pulmonary hypertension (PH), in focused talks geared toward ...
(Date:7/7/2020)... ... July 07, 2020 , ... Halifax-based startup, ... as a hair service provider. Now called Bright, the company has launched a ... offering includes beauty amenities as well as an array of well-being services that ...
(Date:7/2/2020)... ... July 02, 2020 , ... Exercise.com, the fitness industry’s leading tech company specializing ... were logged through its software during the months of May and June. This announcement ... an age where even gym giants like 24 Hour Fitness and ...
Breaking Medicine Technology:
Cached News: